Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).
Mohamed E. Salem, MD
Advertisement
Articles by Mohamed E. Salem, MD
It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes in metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Salem on the Results of the MyPathway Trial in mCRCPublished: April 3rd 2019 | Updated:
Tumor Location Insights in mCRC Challenge Standard of CarePublished: December 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5